 Sanjaya Viswamitra
Concepts (124)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging | 6 | 2023 | 1529 | 0.830 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2022 | 125 | 0.790 |
Why?
| | Skull | 1 | 2022 | 77 | 0.770 |
Why?
| | Heart | 1 | 2023 | 336 | 0.710 |
Why?
| | Spondylitis | 1 | 2019 | 1 | 0.680 |
Why?
| | Tuberculosis, Spinal | 1 | 2019 | 5 | 0.680 |
Why?
| | Spinal Neoplasms | 1 | 2019 | 30 | 0.660 |
Why?
| | Spine | 1 | 2019 | 91 | 0.640 |
Why?
| | Arthritis, Rheumatoid | 1 | 2019 | 105 | 0.640 |
Why?
| | Magnetic Resonance Imaging, Cine | 4 | 2022 | 60 | 0.570 |
Why?
| | Cardiomyopathies | 2 | 2022 | 116 | 0.550 |
Why?
| | Myocardium | 2 | 2023 | 443 | 0.500 |
Why?
| | Myocardial Ischemia | 2 | 2022 | 117 | 0.400 |
Why?
| | Amyloidosis | 1 | 2012 | 78 | 0.380 |
Why?
| | Diagnosis, Differential | 2 | 2022 | 1041 | 0.280 |
Why?
| | Spinal Injuries | 1 | 2005 | 14 | 0.260 |
Why?
| | Cervical Vertebrae | 1 | 2005 | 58 | 0.250 |
Why?
| | Sensitivity and Specificity | 2 | 2022 | 871 | 0.250 |
Why?
| | Anesthesia | 1 | 2005 | 73 | 0.240 |
Why?
| | Intubation, Intratracheal | 1 | 2005 | 120 | 0.230 |
Why?
| | Inpatients | 1 | 2005 | 193 | 0.230 |
Why?
| | Humans | 20 | 2023 | 50201 | 0.210 |
Why?
| | Mitral Valve Stenosis | 1 | 2022 | 7 | 0.200 |
Why?
| | Middle Aged | 11 | 2022 | 12356 | 0.200 |
Why?
| | Trigeminal Neuralgia | 1 | 2022 | 5 | 0.200 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2023 | 243 | 0.190 |
Why?
| | Evoked Potentials, Visual | 1 | 2021 | 37 | 0.190 |
Why?
| | Huntington Disease | 1 | 2021 | 23 | 0.190 |
Why?
| | Diffusion Tensor Imaging | 1 | 2022 | 92 | 0.190 |
Why?
| | Cor Triatriatum | 1 | 2021 | 3 | 0.180 |
Why?
| | Contrast Media | 4 | 2022 | 186 | 0.170 |
Why?
| | Retrospective Studies | 4 | 2022 | 6190 | 0.170 |
Why?
| | Gadolinium | 3 | 2022 | 42 | 0.170 |
Why?
| | Preoperative Care | 1 | 2021 | 167 | 0.170 |
Why?
| | Diagnostic Errors | 1 | 2019 | 66 | 0.160 |
Why?
| | Predictive Value of Tests | 3 | 2022 | 921 | 0.140 |
Why?
| | Synovitis | 1 | 2017 | 21 | 0.140 |
Why?
| | Tomography, X-Ray Computed | 2 | 2021 | 1160 | 0.140 |
Why?
| | Ventricular Function, Left | 2 | 2022 | 158 | 0.140 |
Why?
| | Neoplasms, Connective and Soft Tissue | 1 | 2016 | 1 | 0.130 |
Why?
| | Chondrosarcoma | 1 | 2016 | 10 | 0.130 |
Why?
| | Aspartic Acid | 1 | 2016 | 49 | 0.130 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2017 | 224 | 0.120 |
Why?
| | Aged | 3 | 2022 | 9505 | 0.120 |
Why?
| | Female | 8 | 2022 | 26829 | 0.120 |
Why?
| | Male | 8 | 2022 | 25572 | 0.120 |
Why?
| | Child, Preschool | 1 | 2022 | 3896 | 0.110 |
Why?
| | Adult | 3 | 2022 | 13486 | 0.100 |
Why?
| | Young Adult | 1 | 2022 | 4052 | 0.100 |
Why?
| | Brain | 2 | 2021 | 1311 | 0.100 |
Why?
| | Prostatic Neoplasms | 2 | 2006 | 393 | 0.100 |
Why?
| | Takotsubo Cardiomyopathy | 1 | 2012 | 20 | 0.100 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 280 | 0.100 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2012 | 105 | 0.090 |
Why?
| | Pelvic Pain | 1 | 2010 | 17 | 0.090 |
Why?
| | Varicose Veins | 1 | 2010 | 19 | 0.090 |
Why?
| | Image Enhancement | 1 | 2010 | 54 | 0.090 |
Why?
| | Adolescent | 1 | 2022 | 6459 | 0.090 |
Why?
| | Magnetic Resonance Angiography | 1 | 2010 | 71 | 0.090 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2010 | 65 | 0.090 |
Why?
| | Ovary | 1 | 2010 | 114 | 0.090 |
Why?
| | Cancer Vaccines | 1 | 2010 | 78 | 0.080 |
Why?
| | Child | 1 | 2022 | 6862 | 0.080 |
Why?
| | Dendritic Cells | 1 | 2010 | 133 | 0.080 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 1176 | 0.080 |
Why?
| | Melanoma | 2 | 2017 | 281 | 0.080 |
Why?
| | Reproducibility of Results | 2 | 2022 | 1195 | 0.070 |
Why?
| | Radiography | 2 | 2005 | 485 | 0.070 |
Why?
| | Stroke Volume | 2 | 2022 | 132 | 0.070 |
Why?
| | Fibrosis | 1 | 2007 | 178 | 0.070 |
Why?
| | Renal Insufficiency | 1 | 2007 | 108 | 0.070 |
Why?
| | Iron | 1 | 2007 | 122 | 0.070 |
Why?
| | Skin Diseases | 1 | 2007 | 114 | 0.070 |
Why?
| | Pheochromocytoma | 1 | 2006 | 36 | 0.060 |
Why?
| | Immobilization | 1 | 2005 | 14 | 0.060 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2006 | 51 | 0.060 |
Why?
| | Time Factors | 1 | 2012 | 2909 | 0.060 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2005 | 23 | 0.060 |
Why?
| | Neoplasms, Second Primary | 1 | 2006 | 74 | 0.060 |
Why?
| | Laryngoscopy | 1 | 2005 | 59 | 0.060 |
Why?
| | Retinal Neoplasms | 1 | 2005 | 13 | 0.060 |
Why?
| | Orbital Neoplasms | 1 | 2005 | 30 | 0.060 |
Why?
| | Myocardial Reperfusion | 1 | 2004 | 8 | 0.060 |
Why?
| | Coronary Angiography | 1 | 2004 | 353 | 0.050 |
Why?
| | Trigeminal Nerve | 1 | 2022 | 8 | 0.050 |
Why?
| | Ventricular Remodeling | 1 | 2022 | 53 | 0.050 |
Why?
| | Benchmarking | 1 | 2022 | 61 | 0.050 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2022 | 246 | 0.050 |
Why?
| | Heart Ventricles | 1 | 2022 | 252 | 0.040 |
Why?
| | Prognosis | 1 | 2004 | 1963 | 0.040 |
Why?
| | Prospective Studies | 1 | 2022 | 2396 | 0.030 |
Why?
| | Multiple Myeloma | 1 | 2010 | 2934 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2010 | 2188 | 0.030 |
Why?
| | Immunotherapy | 1 | 2017 | 235 | 0.030 |
Why?
| | Heart Defects, Congenital | 1 | 2021 | 590 | 0.030 |
Why?
| | Cardiovascular Agents | 1 | 2012 | 54 | 0.020 |
Why?
| | Myocardial Contraction | 1 | 2012 | 110 | 0.020 |
Why?
| | Recovery of Function | 1 | 2012 | 188 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2012 | 5203 | 0.020 |
Why?
| | Immunoglobulin Idiotypes | 1 | 2010 | 5 | 0.020 |
Why?
| | CD40 Ligand | 1 | 2010 | 14 | 0.020 |
Why?
| | Hypersensitivity, Delayed | 1 | 2010 | 19 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2010 | 44 | 0.020 |
Why?
| | Phlebography | 1 | 2010 | 60 | 0.020 |
Why?
| | Immunity, Cellular | 1 | 2010 | 69 | 0.020 |
Why?
| | Adjuvants, Immunologic | 1 | 2010 | 51 | 0.020 |
Why?
| | Electrocardiography | 1 | 2012 | 259 | 0.020 |
Why?
| | Endosonography | 1 | 2010 | 94 | 0.020 |
Why?
| | Syndrome | 1 | 2010 | 239 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2010 | 176 | 0.020 |
Why?
| | Embolization, Therapeutic | 1 | 2010 | 88 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 2010 | 175 | 0.020 |
Why?
| | Vaccination | 1 | 2010 | 275 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2007 | 195 | 0.020 |
Why?
| | Adrenalectomy | 1 | 2006 | 35 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2010 | 987 | 0.020 |
Why?
| | Prostate-Specific Antigen | 1 | 2006 | 47 | 0.020 |
Why?
| | Synaptophysin | 1 | 2005 | 7 | 0.020 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2005 | 8 | 0.020 |
Why?
| | Biopsy, Fine-Needle | 1 | 2006 | 108 | 0.020 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2005 | 22 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2005 | 183 | 0.010 |
Why?
| | Neoplasm Metastasis | 1 | 2005 | 235 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2010 | 3158 | 0.010 |
Why?
|
|
Viswamitra's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|